|Table of Contents|

Predictive value of peripheral blood lymphocyte-to-monocyte ratio on efficacy of neoadjuvant chemotherapy for triple negative breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
810-814
Research Field:
Publishing date:

Info

Title:
Predictive value of peripheral blood lymphocyte-to-monocyte ratio on efficacy of neoadjuvant chemotherapy for triple negative breast cancer
Author(s):
LI Caimao
Department of Breast,the Fifth People's Hospital of Qinghai Province，Qinghai Xining 810000,China.
Keywords:
lymphocyte-to-monocyte ratio; triple negative breast cancer; neoadjuvant chemotherapy; chemotherapy efficacy
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2022.05.011
Abstract:
Objective:To investigate the predictive value of peripheral blood lymphocyte-to-monocyte ratio(LMR) on efficacy of neoadjuvant chemotherapy(NAC) for patients with triple negative breast cancer(TNBC).Methods:A total of 100 TNBC patients who received NAC treatment in our hospital from January 2017 to December 2019 were collected.All patients were treated with NAC,and the short-term efficacy was observed.The peripheral blood LMR was detected,and receiver operating characteristic curve was used to determine the cutoff value of LMR.The patients were divided into the high LMR group and the low LMR group,and the relationship between peripheral blood LMR before chemotherapy and NAC efficacy was explored.Results:Among 100 TNBC patients,the effective rate of NAC treatment was 74.00%(74/100),including 6 cases of CR and 68 cases of PR.The clinical ineffective rate was 26.00%(26/100),including 24 cases of PD and 2 cases of SD.ROC curve analysis showed that the area under the curve of peripheral blood LMR in predicting the efficacy of NAC was 0.884(95%CI:0.805~0.939),and the cutoff value was 4.56.Univariate analysis showed that NAC efficacy was not correlated with age(χ2=0.661,P=0.416),T stage(χ2=3.774,P=0.052),lymph node metastasis(χ2=0.674,P=0.412) and clinical stage(χ2=0.630,P=0.427),but was correlated with the Ki-67 level(χ2=6.971,P=0.008) and LMR value(χ2=10.695,P=0.001).The chemotherapy effective rate of the high Ki-67 expression group was higher than that of the low expression group(84.91% vs 61.70%),and the chemotherapy effective rate of the high LMR group(>4.56) was higher than that of the low LMR group(≤4.56)(86.21% vs 57.14%)(P＜0.05).Multivariate Logistic regression analysis showed that high LMR level(OR=0.286,95%CI:0.105~0.781) and high Ki-67 expression(OR=0.328,95%CI:0.129~0.834) both were beneficial factors for NAC efficacy of TNBC patients(P＜0.05).Conclusion:Peripheral blood LMR has predictive value on NAC efficacy in TNBC patients,and high LMR level may indicate better efficacy.

References:

[1]PERRIER A，GLIGOROV J，GUILLAUME L,et al.The extracellular domain of Her2 in serum as a biomarker of breast cancer［J］.Lab Invest,2018,98(6):696-707.
[2]YUKA A，SHINICHIRO K，WATARUG，et al.Expression and clinical significance of androgen receptor in triple negative breast cancer［J］.Cancers,2017,9(12):585-590.
[3]王一,廖宏伟,宋扬.三阴性乳腺癌患者新辅助化疗过程中血清维生素D,维生素B12,叶酸水平变化与化疗效果的关系［J］.山东医药,2017,57(27):96-98. WANG Y,LIAO HW,SONG Y.Relationship between changes of serum vitamin D,vitamin B12 and folic acid and effect of chemotherapy in patients with triple-negative breast cancer during neoadjuvant chemotherapy［J］.Shandong Med,2017,57(27):96-98.
[4]彭翅,肖萤.三维及彩色多普勒超声评估乳腺癌新辅助化疗疗效的价值［J］.中国现代医学杂志,2018,28(35):78-82. PENG C,XIAO Y.Study of three-dimensional and color Doppler ultrasonography in evaluating the effect of neoadjuvant chemotherapy for breast cancer［J］.Chin J Modern Med,2018,28(35):78-82.
[5]林小慧,许梅,马捷.采用MRI评估不同分子分型乳腺癌新辅助化疗的疗效［J］.中华放射学杂志,2019,53(11):1020-1024. LIN XH,XU M,MA J.The progress of current MRI for predicting the response of different molecular subtypes of breast cancer to neoadjuvant chemotherapy［J］.Chin J Radiol,2019,53(11):1020-1024.
[6]SUN Y，LI W，LI AJ，et al.Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative,HER2-positive breast cancer patients［J］.Cancer Manag Res,2019,11:3153-3162.
[7]李黎,李曙光,闫可,等.外周血淋巴细胞与单核细胞比值变化对食管癌调强放疗预后影响［J］.中华放射肿瘤学杂志,2019,28(10):741-745. LI L,LI SG,YAN K,et al.Effect of peripheral blood lymphocyte-to-monocyte ratio on prognosis of esophageal cancer patients treated with intensity-modulated radiotherapy［J］.Chin J Radiat Oncol,2019,28(10):741-745.
[8]徐辉,张汝一,姬清华,等.结直肠癌远处转移患者治疗前LMR值与化疗疗效和死亡风险的相关性研究［J］.中国现代医学杂志,2018，28（6）：76-80. XU H,ZHANG RY,JI QH,et al.Prognostic value of LMR on patients with distant metastasis of colorectal cancer prior to therapeutic interventions［J］.Chin J Modern Med,2018,28(6):76-80.
[9]郑美珠,魏玲,郑刚,等.汉族女性乳腺癌患者has-miR-125a-5p基因的rs12975333位点的单核苷酸多态性及其在癌组织中的表达研究［J］.中华普通外科杂志,2011,26(7):596-599. ZHENG MZ,WEI L,ZHENG G,et al.Relationship between the single nucleotide polymorphisms in has-miR-125a-5p rs12975333 and expression of has-miR-125a-5p in Han Chinese female breast cancer patients［J］.Chin J Gen Surg,2011,26(7):596-599.
[10]杨文涛,步宏.乳腺癌雌、孕激素受体免疫组织化学检测指南［J］.中华病理学杂志,2015,44(4):237-239. YANG WT,BU H.Guidelines for immunohistochemical detection of estrogen and progesterone receptors of breast cancer［J］.Chin J Pathol,2015,44(4):237-239.
[11]HAYES DF.Assessment of Ki67 in breast cancer:Recommendations from the International Ki67 in Breast Cancer Working Group［J］.J Natl Cancer Inst,2011,103(22):1656-1664.
[12]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2013版)［J］.中国癌症杂志,2013,23(8):637-684. Breast Cancer Professional Committee of Chinese Anti-Cancer Association.Guidelines and norms for diagnosis and treatment of breast cancer of Chinese anti-cancer association(2013 Edition)［J］.Chin Oncol,2013,23(8):637-684.
[13]杨辉,江皓.新辅助TAC化疗对早期乳腺癌患者疗效、细胞免疫功能和Ki-67的影响［J］.中华全科医学,2017,15(4):555-557. YANG H,JIANG H.Influence of neoadjuvant chemotherapy of TAC on curative effect,cellular immunity and Ki-67 expression in early breast cancer patients［J］.Chin J Gen Prac,2017,15(4):555-557.
[14]吴瑶瑶,崔浩,章龙珍.全脑放疗联合靶向治疗与同步放化疗治疗非小细胞肺癌脑转移的疗效及不良反应的Meta分析［J］.现代肿瘤医学，2019,27(12):2091-2096. WU YY,CUI H,ZHANG LZ.Whole brain radiation therapy plus target therapy versus concurrent chemoradiotherapy in treatment of brain metastases of NSCLC［J］.Modern Oncology,2019,27(12):2091-2096.
[15]JAYAKUMAR H,RAMANATHAN P,SUBRAMANI J,et al.Analysis of Kynurenine/Tryptophan ratio and expression of IDO1 and 2 mRNA in tumour tissue of cervical cancer patients［J］.Clin Biochem,2016,49(12):919-924.
[16]朱坤兵,徐灿,李晓霞,等.乳腺癌分子分型与新辅助化疗效果的关系［J］.中华乳腺病杂志（电子版）,2016,10(3):166-169. ZHU KB,XU C,LI XX,et al.Correlation between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer patients［J］.Chin J Breast Dis(Electronic Edition),2016,10(3):166-169.
[17]左文述,郑美珠,韩超.新辅助化疗对可手术乳腺癌患者总体治疗策略影响的思考［J］.中华肿瘤杂志,2017,39(12):952-957. ZUO WS,ZHENG MZ,HAN C.Effect of neoadjuvant chemotherapy on the overall treatment strategy in operable breast cancer［J］.Chin J Oncol,2017,39(12):952-957.
[18]MAN YG，ALEXANDER S，JEFFREY M，et al.Tumor-infiltrating immune cells promoting tumor invasion and metastasis:Existing theories［J］.J Cancer,2013,4(1):84-95.
[19]UBUKATA H,MOTOHASHI G,TABUCHI T,et al.Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients［J］.J Surg Oncol,2010,102(7):742-747.
[20]SHIBUTANI M，MAEDA K，NAGAHARA H，et al.Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer［J］.Oncol Lette,2017,13(2)：1000-1006.
[21]NAZIR T，ISAM A，OMER MO，et al.Lymphocytopenia,induced by vinorelbine,doxorubicin and cisplatin in human cancer patients［J］.Breast Disease,2015,35(1):1-4.
[22]张胜楠,李梦娟,袁芳芳,等.动态监测外周血淋巴细胞与单核细胞比值对弥漫大B细胞淋巴瘤患者的疗效判断和预后指导意义［J］.中华医学杂志,2019,99(40):3139-3144. ZHANG SN,LI MJ,YUAN FF,et al.Efficacy and prognosis of the dynamic monitoring lymphocyte to monocyte ratio in patients with diffuse large B-cell lymphoma［J］.Natl Med J China,2019,99(40):3139-3144.
[23]LIN XM,LI MH，ZHAO F，et al.The lymphocyte-monocyte ratio predicts tumor response and survival in patients with locally advanced esophageal cancer who received definitive chemoradiotherapy［J］.Oncotarg Ther,2017,10:871-877.
[24]GAO XP,LIU YH,LIU ZY,et al.Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer:a meta-analysis［J］.Cancer Manag Res,2019,11:1907-1920.
[25]贾韬,朱华渊,王莉,等.外周血淋巴细胞/单核细胞比值及2个疗程后PET评价在成人霍奇金淋巴瘤中的预后意义［J］.中华血液学杂志,2019,40(5):372-377. JIA T,ZHU HY,WANG L,et al.The prognostic significance of peripheral lymphocyte/monocyte ratio and PET-2 evaluation in adult Hodgkin' s lymphoma［J］.Chin J Hematol,2019,40(5):372-377.
[26]王敬华,郑美珠,李永清.乳腺癌免疫组化分子分型与新辅助化疗疗效相关性分析［J］.中华肿瘤防治杂志,2018,25(010):704-708. WANG JH,ZHENG MZ,LI YQ.Correlation analysis between immunohistochemical molecular typing of breast cancer and neoadjuvant chemotherapy efficacy［J］.Chin J Cancer Preven & Treat,2018,25(010):704-708.

Memo

Memo:
青海省卫生计生系统科研课题(编号：2016-wjzd-10)
Last Update: 2022-01-27